title: Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
authors.affiliation: The University of Alabama at Birmingham, Birmingham, AL, United States. Electronic address: rdalvarez@uab.edu.
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, United States.
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
authors.affiliation: UC Cancer Institute, The University of Cincinnati, Cincinnati, OH, United States.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Herzog
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Coleman
authors.affiliation: University of Arizona Cancer Center, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.affiliation: Cancer Treatment Centers of America, Philadelphia, PA, United States.
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
mesh_terms: D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
chemical_list: D009944:Organoplatinum Compounds
keywords: Platinum sensitive/resistant; Recurrent ovarian cancer